TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Isokinetic strength testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in short form-36 (SF-36) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The functional level of dexterity and coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dexterity-related activity limitations in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Presence of neuromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NGF (Nerve Growth Factor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: αSMA (Alpha-Smooth Muscle Actin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonographic Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall body surface area involvement (%BSA-AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decisional self-efficiency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety and tolerability of misoprostol
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Annualized Metabolic Decompensation Events (MDEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of patellar dislocations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting systolic blood pressure from baseline to 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Nitric Oxide-mediated Endothelium Dependent Dilation (EDD) from baseline to 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lumbopelvic kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbopelvic control ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gene expression associated with atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Types and concentrations of cfDNA and proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Invasive Tear Break Up Time (NITBUT) duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Body surface area and location from the Psoriasis Draw assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quantification and distribution of self-reported painful joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total number of reinterventions required for treatment success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Minimally important clinical change in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural Competency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T-KAB TOTAL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concentration of leukocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of neutrophil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CPAP/NIS weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of sleep impairment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Serum PK AUC for CUE-102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of materials used in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in range of motion of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in pain on the 10-point Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in quality of life with the Short Form 36 Health Survey Questionnaire (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Core biopsy tissue evaluability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant Recurrence Free Interval (dRFI)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of DLT events within 28 days
Endpoint domain: Adverse events/effects
Primary endpoint: Time to perform the anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence rate of anastomotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Nottingham Extended Activities Of Daily Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frenchay Activities Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tinetti scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipopolysaccharide binding protein plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: postoperative pelvic sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: pelvic abscess
Endpoint domain: Adverse events/effects
Primary endpoint: peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with confirmed SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Circulatory vitamin B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LIMA free flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with mRS ≤ 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soluble markers of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukocytosis in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CRP in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: procalcitonine in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fibrinogen in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ferritin in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IL-1 in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of children with SpHb <12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chronic Change in Resting Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chronic Change in Ambulatory Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chronic Change in Brain Structure and Function measured by Magnetic Resonance Imaging Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharyngeal constrictor muscle function as estimated by the pharyngeal area at maximum constriction (PhAMPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Temporal muscle flap patient questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antebrachial flap patient questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Half effective dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥2 neurotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in FACT/GOG-Ntx score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUCnic 0-180 mins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel movement frequency and characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numerical Rating Scale (NPRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: DVT & PE Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of completed training sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of repetitions per session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who dropout from substance use services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of missed sessions and no show sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Genital tract inflammation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Percent Change in Body Weight (Azelaprag Once per Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change in Body Weight (Azelaprag Twice per Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of HPR to LPR patients based on PCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Interference Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Emerging Adult Perceptions of Acceptability of the Launch Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent Perceptions of Acceptability of the Launch Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emerging Adult Client Satisfaction with Launch Services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worse glycated hemoglobin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Worse LDL cholesterol value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Higher BMI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Higher BP (blood pressure) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from pretreatment baseline in the WOMAC pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Function Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mental Health Continuum-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean Titer (GMT) of Serum SARS-CoV-2 Binding Antibody Titers Against Omicron BA.4/5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio (GMR) of GMT of Serum SARS-CoV-2 Binding Antibody Concentrations Against Omicron XBB.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of treatment-related sexual dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Development of chronic abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ages and Stages Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent correct speech intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response within the radiated volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Tampa Scale of Kinesiophobia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained abstinence at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Canadian Cardiovascular Society angina class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain assessment using FLACC Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International prostate symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detrusor activity recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale (VAS) pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia impact scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in blood concentration of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Score of the Body Shape Questionnaire (BSQ-34)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mass spectrometry profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of GPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's perspective on telemedicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toxicity or Discontinuation of Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of cardiac dysfunction or heart valve disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eyberg Child Behavior Inventory (ECBI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in physical Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Ambulatory Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended dose for subsequent study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function measure test 32 (MFM32)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static balance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic balance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cardiovagal Baroreflex Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure reactivity to the cold pressor test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in exercise pressor reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in beat-to-beat blood pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in renal vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Premature Infant Pain Profile - PIPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic threshold (mA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effect threshold (mA)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Diphenhydramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC [0-t]) for Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC [0-t]) for Diphenhydramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC [0-inf]) for Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary Histatine-5 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mood as assessed by BDI-ll
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in total mood disturbance as assessed by POMS Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in sitting behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of CBD use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COPD Symptoms Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COPD Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Somatic and psychoactive effects reported from use of kratom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Associations between self-reported states and kratom dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detect Concentrations of detectable kratom alkaloids and their metabolites in human plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression of Change (PGIC) response rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Female sexual function index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Sexual distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage change in pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of LN treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T cell number and phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local and/or regional disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Migraine attacks monthly frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Impact Test (HIT-6) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain killer drugs monthly taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Electroclinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of fever in days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Wake Time (TWT)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: FMA-Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative successful obturator nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of bundled interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of dementia and mild cognitive impairment
Endpoint domain: Mortality/survival
Primary endpoint: Attempts to successful catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stationary free throw performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinosinusitis Disability Index (RSDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median Endoscopic Ultrasound (EUS) Shear Wave Elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin autofluorescence for AGEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total cholesterol (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes